From whole blood to component therapy: The economic, supply/demand need for implementation of component therapy in sub-Saharan Africa

Transfusion Clinique et Biologique

Volumn 18, Issue 5-6, 2011, Pages 516-526

  Erhabor, O ^a   Adias, T C ^b  

^a ROYAL BOLTON HOSPITAL   (United Kingdom)

^b RIVERS STATE UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Nigeria)

Author keywords

Component therapy; Demand; Sub Saharan Africa; Supply; Whole blood

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ALBUMIN; ALPHA 1 ANTITRYPSIN; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CEFOTAXIME; GRIFOLS; IMMUNOGLOBULIN; RECOMBINANT BLOOD CLOTTING FACTOR 9; UNCLASSIFIED DRUG;

AFRICA; ALLOTRANSPLANTATION; ALPHA 1 ANTITRYPSIN DEFICIENCY; BLEEDING; BLOOD DONOR; BLOOD TRANSFUSION; CLINICAL EFFECTIVENESS; CRYOPRECIPITATE; DEVELOPING COUNTRY; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; HEMOPHILIA A; HEMOPHILIA B; HUMAN; INFECTION RISK; LEUKOCYTE TRANSFUSION; PLASMA TRANSFUSION; PLASMAPHERESIS; RISK FACTOR; SAFETY; SHORT SURVEY; SURVIVAL RATE; THROMBOCYTE TRANSFUSION; TREATMENT INDICATION; TREATMENT RESPONSE; VON WILLEBRAND DISEASE;

AFRICA SOUTH OF THE SAHARA; ALPHA 1-ANTITRYPSIN; BLOOD COAGULATION FACTORS; BLOOD COMPONENT TRANSFUSION; BLOOD DONORS; BLOOD SAFETY; BLOOD TRANSFUSION; FACTOR VIII; FIBRINOGEN; HEALTH POLICY; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; LEUKOCYTE REDUCTION PROCEDURES; VIRUS DISEASES;

EID: 82555170327     PISSN: 12467820     EISSN: 19538022     Source Type: Journal    
DOI: 10.1016/j.tracli.2011.06.001     Document Type: Short Survey

References (93)

1. Sweeney J.D. Standardization of the red cell product. Transfus Apher Sci 2006, 34:213-218.
2. Meyer D., Bolgiano D.C., Sayers M., Price T., Benson D., Slichter S.J. Red cell collection by apheresis technology. Transfusion 1993, 33:819-824.
3. Solheim B.G. Pathogen reduction of blood components. Transfus Apher Sci 2008, 39:75-81.
4. Radhakrishnan K.M., Chakravarthi S., Pushkala S., Javaraju J. Component therapy. Indian J Pediatr 2003, 70:661-666.
5. Bordin J.O., Heddle N.M., Blajchman M.A. Biologic effects of leukocytes present in transfused cellular blood products. Blood 1994, 84:1703-1721.
6. Zhao S.M., Lin W.C., Liu J.H. Leucocyte removal and its clinical application. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2002, 10:478-482.
7. MacLennan S., Murphy M.F. Survey of the use of whole blood in current blood transfusion practice. Clin Lab Hematol 2001, 23:391-396.
8. Kauvar D.S., Holcomb J.B., Norris G.C., Hess J.R. Fresh whole blood transfusion: a controversial military practice. J Trauma 2006, 61:181-184.
9. Spinella P.C. Warm fresh whole blood transfusion for severe haemorrhage: U.S. military and potential civilian applications. Crit Care Med 2008, 36:340-345.
10. Repine T.B., Perkins J.G., Kauvar D.S., Blackborne L. The use of fresh whole blood in massive transfusion. J Trauma 2006, 60:59-69.
11. Spinella P.C., Perkins J.G., Grathwohl K.W., Repine T., Beekley A.C., Sebesta J., et al. Fresh whole blood transfusions in coalition military, foreign national and enemy combatant patients during Operation Iraqi Freedom at a U.S. combat support hospital. World J Surg 2008, 32:2-6.
12. Knight K., Wade S., Balducci L. Prevalence and outcomes of anaemia in cancer: a systematic review of the literature. Am J Med 2004, 116:11S-26S.
13. Napolitano L.M., Kurek S., Luchette F.A., Corwin H.L., Barie P.S., Tisherman S.A., et al. Clinical practice guideline: red blood cell transfusion in adult trauma and critical care. Crit Care Med 2009, 37:124-157.
14. Pedersen A.B., Mehnert F., Overgaard S., Johnsen S.P. Allogeneic blood transfusion and prognosis following total hip replacement: a population-based follow up study. BMC Musculoskelet Disord 2009, 10:167.
15. Ludwig H., Van Belle S., Barrett-Lee P., Birgegard G., Bokemeyer C., Gascon P., et al. The European Anaemia Cancer Survey (ECAS): a large multinational, prospective survey defining the prevalence, incidence and treatment of anaemia in cancer patients. Eur J Cancer 2004, 40:2293-2306.
16. Mell M.W., O' Niel A.S., Callcut R.A., Acher C.W., Hoch J.R., Tafera G., et al. Effect of early plasma transfusion on mortality in patients with ruptured abdominal aortic aneurysm. Surgery 2010, 18:955-962.
17. Nikolsky E., Avmong E.D., Halkin A., Grines C.L., Cox D.A., Garcia E., et al. Impact of anaemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. J Am Coll Cardiol 2004, 44:547-553.
18. Corwin H.L., Gettinger A., Pearl R.G., Fink M.P., Levy M.M., Abraham E., et al. The CRIT Study: anaemia and blood transfusion in the critically ill-current clinical practice in the United States. Crit Care Med 2004, 32:39-52.
19. Padmanabhan A., Schwartz J., Spitalnik S.L. Transfusion therapy in postpartum hemorrhage. Semin Perinatol 2009, 33:124-127.
20. Bonnar J. Massive obstetric haemorrhage. Baillieres Best Pract Res Clin Obstet Gynaecol 2000, 14:1-18.
21. Heerbshaw S., Brunskill S., Doree C., Hyde C., Travis S., Murphy M.F. Red cell transfusion for the management of upper gastrointestinal haemorrhage. Cochranne Database Syst Rev 2009, 15:CD006613.
22. Hess J.R. Red cell freezing and its impact on the supply chain. Transfus Med 2004, 14:1-8.
23. McCullough J., Haley R., Clay M., Hubel A., Lindgren B., Moroff G. Long-term storage of peripheral blood stem cells frozen and stored with a conventional liquid nitrogen technique compared with cells frozen and stored in a mechanical freezer. Transfusion 2010, 50:808-819.
24. Peyrard T., Pham B.N., Le Pennec P.Y., Rouger P. Transfusion of rare cryopreserved red blood cell units stored at -80 degrees centigrade: the French experience. Immunohematology 2009, 25:13-17.
25. Ariga H., Lee T.H., Laycock M.E., Mohr B.A., Kalish L.A., Yomtovian R., et al. Viral Activation Transfusion Study. Residual WBC subsets in filtered prestorage RBCs. Transfusion 2003, 43:98-106.
26. Bowden R.A., Slichter S.J., Sayers M., Weisdorf D., Cays M., Schoch G., et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995, 86:3598-3603.
27. Aye M.T., Palmer D.S., Giulivi A., Hashemi S. Effect of filtration of platelet concentrates on the accumulation of cytokines and platelet release factors during storage. Transfusion 1995, 35:117-124.
28. Klein M.A., Frigg R., Raeber A.J., Flechsig E., Hegyi I., Zinkernagel R.M., et al. PrP expression in B lymphocytes is not required for prion neuroinvasion. Nat Med 1998, 4:1429-1433.
29. Baron J.F., Gourdin M., Bertrand M., Mercadier A., Delort J., Kieffer E., et al. The effect of universal leukodepletion of packed red blood cells on postoperative infections in high-risk patients undergoing abdominal aortic surgery. Anesth Analg 2002, 94:529-537.
30. Jean-François B., Maximilien G., Michèle B., Anne M., Josée D., Edouard K., et al. The effect of universal leukodepletion of packed red blood cells on postoperative infections in high-risk patients undergoing abdominal aortic surgery. Anesth Analg 2002, 94:529-537.
31. García-Alvarez F., Al-Ghanem R., García-Alvarez I., López-Baisson A., Bernal M. Risk factors for postoperative infections in patients with hip fracture treated by means of Thompson arthroplasty. Arch Gerontol Geriatr 2010, 50:51-55.
32. Klos M., Korsak J. Immunomodulatory effect of blood components transfusions. Pol Merkur Lekarski 2002, 13:413-416.
33. Chen W., Diao J., Stepkowski S.M., Zhang L. Both infiltrating regulatory T cells and insufficient antigen presentation are involved in long-term cardiac xenograft survival. J Immunol 2007, 179:1542-1548.
34. Blajchman M.A. Transfusion immunomodulation or TRIM: what does it mean clinically?. Hematology 2005, 10:208-214.
35. Dara S.I., Rana R., Afessa B., Moore S.B., Gajic O. Fresh frozen plasma transfusion in critically ill medical patients with coagulopathy. Crit Care Med 2005, 11:2714-2716.
36. Teixeira P.G., Inaba K., Shulman I., Salim A., Dametriades D., Brown C., et al. Impact of plasma transfusion in massively transfused trauma patients. J Trauma 2009, 66:693-697.
37. Vlaar A.P., in der Maur A.L., Binnekade J.M., Schultz M.J., Juffermans N.P. A survey of physicians' reasons to transfuse plasma and platelets in the critically ill: a prospective single-centre cohort study. Transfus Med 2009, 4:207-212.
38. MacLennan S., Williamson L.M. Risks of fresh frozen plasma and platelets. J Trauma 2006, 60:s46-s50.
39. O'Shaughnessy D.F., Atterbury C., Bolton Maggs P., Murphy M., Thomas D., Yates S., et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004, 126:11-28.
40. Medical Directors Advisory Committee, National Blood Transfusion Council S Afr Med J 1998, 88:1344-1347.
41. Aiyagari V., Testai F.D. Correction of coagulopathy in warfarin associated cerebral hemorrhage. Curr Opin Crit Care 2009, 15:87-92.
42. Dentali F., Crowther M.A. Management of excessive anticoagulant effect due to vitamin K antagonists. Hematol Am Soc Hematol Educ Program 2008, 266-270.
43. Goldstein J.N., Rosand J., Schwamm L.H. Warfarin reversal in anticoagulant-associated intracerebral hemorrhage. Neurocrit Care 2008, 9:277-283.
44. Tzomalos K., Vakalopoulou S., Perifanis V., Garipidou V. Treatment of congenital fibrinogen deficiency: overview and recent findings. Vasc Health Risk Manag 2009, 5:843-848.
45. Federici A.B. The safety of plasma-derived von Willebrand/factor VIII concentrates in the management of inherited von Willebrand disease. Pert Opin Drug Saf 2009, 8:203-210.
46. Levi M., Toh C.H., Thachil J., Watson H.G. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 2009, 145:24-33.
47. Jackson G.N., Snowden C.A., Indrikovs A.J. A prospective audit program to determine blood component transfusion appropriateness at a large university hospital: a 5-year experience. Transfus Med Rev 2008, 22:154-161.
48. Slichter S.J. Evidence-based platelet transfusion guidelines. Hematol Am Soc Hematol Educ Program 2007, 172-178.
49. Slichter S.J. Platelet transfusion therapy. Hematol Oncol Clin North Am 2007, 21:697-729.
50. Heal J.M., Blumberg N. Optimizing platelet transfusion therapy. Blood Rev 2004, 18:149-165.
51. The Trial To Reduce Alloimmunization To Platelets Study Group Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997, 337:1861-1869.
52. Vamvakas E.C. Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis. Transfus Med Rev 2005, 19:181-199.
53. Slichter S.J. Relationship between platelet count and bleeding risk in thrombocytopenic patients. Trans Med Rev 2004, 18:153-167.
54. Schiffer C.A., Anderson K.C., Bennett C.L., Bernstein S., Elting L.S., Goldsmith M., et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001, 19:1519-1538.
55. British Committee for Standards in Haematology Guidelines for the use of platelet transfusions. Br J Haematol 2003, 122:10-23. Blood Transfusion Task Force (Chairman P. Kelsey).
56. Slichter S.J. Background, rationale, and design of a clinical trial to assess the effects of platelet dose on bleeding risk in thrombocytopenic patients. J Clin Apheresis 2006, 21:78-84.
57. Heddle N.M., Cook R.J., Sigouin C., Slichter S.J., Murphy M., Rebulla P., et al. A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukemia. Transfusion 2006, 46:903-911.
58. Slichter S.J., Davis K., Enright H., Braine H., Gernsheimer T., Kao K.J., et al. Factors affecting post-transfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005, 105:4106-4114.
59. Aster R.H. Effect of anticoagulant and ABO incompatibility on recovery of transfused human platelets. Blood 1965, 26:732-743.
60. Vamvakas E.C. Meta-analysis of randomized controlled trials of the efficacy of white cell reduction in preventing HLA-alloimmunization and refractoriness to random-donor platelet transfusions. Transfus Med Rev 1998, 12:258-270.
61. Delaflor-Weiss E., Mintz P.D. The evaluation and management of platelet refractoriness and alloimmunization. Transfus Med Rev 2000, 14:180-196.
62. Watts R.G. Idiopathic thrombocytopenic purpura: a 10-year natural history study at the childrens hospital of alabama. Clin Pediatr (Phila) 2004, 43:691-702.
63. Rodeghiero F. First-line therapies for immune thrombocytopenic purpura: re-evaluating the need to treat. Eur J Haematol Suppl 2008;19-26.
64. Cirasino L., Robino A.M., Cattaneo M., Pioltelli P.E., Pogliani E.M., Terranova L., et al. Appropriate hospital management of adult immune thrombocytopenic purpura patients in major Italian institutions in 2000-2002: a retrospective analysis. Blood Coagul Fibrinolysis 2010, 21:77-84.
65. Federici A.B., Castaman G., Franchini M., Morfini M., Zanon E., Coppola A., et al. Clinical use of Haemate P in inherited von Willebrand's disease: a cohort study on 100Italian patients. Haematologica 2007, 92:944-951.
66. Dunkley S., Baker R.I., Pidcock M., Price J., Seldon M., Smith M., et al. Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE in patients with von Willebrand's disease: a prospective multi-centre study. Haemophilia 2010, 16:615-624.
67. Michiels J.J., van Vliet H.H., Berneman Z., Schroyens W., Gadisseur A. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings. Acta Haematol 2009, 121:167-176.
68. Gangrened P. Haemophilia B: christmas disease. Expert Opin Pharmacother 2005, 6:1517-1524.
69. Monahan P.E., Liesner R., Sullivan S.T., Ramirez M.E., Kelly P., Roth D.A. Safety and efficacy of investigator-prescribed BeneFIX prophylaxis in children less than 6 years of age with severe haemophilia B. Haemophilia 2010, 16:460-468.
70. ®, a high-purity factor IX concentrate, in patients with severe haemophilia B. Haemophilia 2009, 16:240-246.
71. Hoots W.K., Leissinger C., Stabler S., Schwartz B.A., White G., Dasani H., et al. Continuous intravenous infusion of a plasma-derived factor IX concentrate (Mononine) in haemophilia B. Haemophilia 2003, 9:164-172.
72. McCall P., Story D.A., Karalapillai D. Audit of factor VIIa for bleeding resistant to conventional therapy following complex cardiac surgery. Can J Anaesth 2006, 53:926-933.
73. Stainsby D., MacLennan S., Thomas D., Isaac J., Hamilton P.J. Guidelines on the management of massive blood loss. Br J Haematol 2006, 135:634-641.
74. Leissinger C.A., Blatt P.M., Hoots W.K., Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol 2008, 83:137-143.
75. Ansell J., Hirsh J., Poller L., Bussey H., Jacobson A., Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126:204S-233S.
76. Steiner T., Kaste M., Forsting M., Mendelow D., Kwiecinski H., Szikora I., et al. Recommendations for the management of intracranial haemorrhage-part I: spontaneous intracerebral haemorrhage. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee. Cerebrovasc Dis 2006, 22:294-316.
77. Kraut E.H., Aledort L.M., Arkin S., Stine K.C., Wong W.Y. Surgical interventions in a cohort of patients with haemophilia A and inhibitors: an experiential retrospective chart review. Haemophilia 2007, 13:508-517.
78. Martinowitz U., Livnat T., Zivelin A., Kenet G. Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors. Haemophilia 2009, 15:904-910.
79. Rodling Wahlström M., Olivecrona M., Nyström F., Koskinen L.O., Naredi S. Fluid therapy and the use of albumin in the treatment of severe traumatic brain injury. Acta Anaesthesiol Scand 2009, 53:18-25.
80. Akech S., Gwer S., Idro R., Fegan G., Eziefula A.C., Newton C.R.J.C., et al. Volume expansion with albumin compared to gelofusine in children with severe malaria: results of a controlled trial. PLoS Clin Trials 2006, 1:e21.
81. Fischer J. Albumin infusions can help some critically ill patients. Dimens Crit Care Nurs 1999, 18:17.
82. Navasa M., Arroyo V., Aldeguer X., Planas R., Ruiz-del-Arbol L., Castells L., et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999, 341:403-409.
83. Carsin H. Human albumin solutions in the treatment of burned patients. Current indications. Presse Med 1997, 26:474-476.
84. Alderson P., Bunn F., Lefebvre C., Li W.P., Li L., Roberts I., et al. Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database Syst Rev 2004, 18:CD001208.
85. Sort P., Garcovich M., Zocco M.A., Gasbarrini A. Clinical use of albumin in hepatology. Blood Transfus 2009, 7:268-277.
86. Branch D.R., Shabani F., Lund N., Denomme G.A. Antenatal administration of Rh-immune globulin causes significant increases in the immunomodulatory cytokines transforming growth factor-β and prostaglandin E2. Transfusion 2006, 46:1316-1322.
87. Ramsey G. Inaccurate doses of R immune globulin after rh-incompatible fetomaternal hemorrhage: survey of laboratory practice. Arch Pathol Lab Med 2009, 133:465-469. College of American Pathologists Transfusion Medicine Resource Committee.
88. Cooper N. Intravenous immunoglobulin and anti-RhD therapy in the management of immune thrombocytopenia. Hematol Oncol Clin North Am 2009, 23:1317-1327.
89. Trebo M.M., Frey E., Gadner H., Minkov M. Subcutaneous anti-D globulin application is a safe treatment option of immune thrombocytopenia in children. Ann Hematol 2010, 89:415-418.
90. Liumbruno G., Bennardello F., Lattanzio A., Piccoli P., Rossetti G. Recommendations for the use of antithrombin concentrates and prothrombin complex concentrates. Blood Transfus 2009, 7:325-334. Italian Society of Transfusion Medicine and Immunohaematology (SIMTI) Working Party.
91. Valentino L.A. The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series. Haemophilia 2009, 15:733-742.
92. Zamora N.P., Pla R.V., Del Rio P.G., Margaleff R.J., Frias F.R., Ronsano J.B. Intravenous human plasma-derived augmentation therapy in alpha 1-antitrypsin deficiency: from pharmacokinetic analysis to individualizing therapy. Ann Pharmacother 2008, 42:640-646.
93. Mordwinkin N.M., Louie S.G. Aralast: an alpha 1-protease inhibitor for the treatment of alpha-antitrypsin deficiency. Expert Opin Pharmacother 2007, 8:2609-2614.